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Abstract
Background: MicroRNA expression is severely disrupted in carcinogenesis, however limited evidence is available validating
results from cell-line models in human clinical cancer specimens. MicroRNA-21 (mir-21) and microRNA-143 (mir-143) have
previously been identified as significantly deregulated in a range of cancers including cervical cancer. Our goal was to
investigate the expression patterns of several well-studied microRNA species in cervical samples and compare the results to
cell line samples.
Methodology/Principal Findings: We measured the expression of mir-21 and mir-143 in 142 formalin-fixed, paraffin
embedded (FFPE) cervical biopsy tissue blocks, collected from Dantec Oncology Clinic, Dakar, Senegal. MicroRNA
expression analysis was performed using Taqman-based real-time PCR assays. Protein immunohistochemical staining was
also performed to investigate target protein expression on 72 samples. We found that mir-21 expression increased with
worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast
to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21
largely unaffected. We also identified, for the first time, that cytoplasmic expression of Programmed Cell Death Protein 4
PDCD4; a known target of mir-21) was significantly lower in women with invasive cervical carcinoma (ICC) in comparison
to those with cervical intraepithelial neoplasia (2–3) or carcinoma in situ (CIN2-3/CIS), although there was no significant
correlation between mir-21 and PDCD4 expression, despite previous studies identifying PDCD4 transcript as a known mir-
21 target.
Conclusions: Whilst microRNA biomarkers have a number of promising features, more studies on expression levels in
histologically defined clinical specimens are required to investigate clinical relevance of discovery-based studies. Mir-21 may
be of some utility in predictive screening, given that we observed a significant correlation between mir-21 expression level
and worsening histological diagnosis of cervical cancer.
Citation: Deftereos G, Corrie SR, Feng Q, Morihara J, Stern J, et al. (2011) Expression of Mir-21 and Mir-143 in Cervical Specimens Ranging from Histologically
Normal through to Invasive Cervical Cancer. PLoS ONE 6(12): e28423. doi:10.1371/journal.pone.0028423
Editor: Alfons Navarro, University of Barcelona, Spain
Received April 22, 2011; Accepted November 8, 2011; Published December 14, 2011
Copyright:  2011 Deftereos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge funding contributions from the National Institutes of Health/National Cancer Institutes (NIH/NCI) (R01 CA75920 and R01
CA115713; Dr. Kiviat) and the American Australian Association (Merck Company Foundation Postdoctoral Fellowship; Dr. Corrie). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nbk@u.washington.edu
Introduction
Early cancer detection strategies are based on the identification
and validation of biomarkers which are highly indicative of disease
progression from normal or precancerous tissue to early invasive
cancers. MicroRNAs are a group of recently discovered short RNA
species (,21 nt) that are involved in the regulation of gene
expression in a tissue-specific manner, affecting numerous cellular
pathways including proliferation, differentiation and apoptosis [1]. It
hasbeenshownthatmicroRNAsareaberrantlyregulatedininvasive
cancer, and can act as tumor suppressors or enhancers in different
tissues and environments [2]. Their recent discovery has led to a
number of studies aimed at discovering novel cancer biomarkers
(reviewed in [3–5]), however few have been validated in clinical
specimens, especially those representative of pre-cancerous disease.
MicroRNAs are of increasing interest in cancer diagnostics due
to the observation that a surprisingly small family of molecules can
provide exquisite specificity in classifying tissue types, reflecting the
developmental lineage and differentiation state. Lu et al. exploited
this by using a microRNA panel of 217 species to classify poorly
differentiated tumors with high concordance whilst a comparable
mRNA panel containing ,16,000 species failed [6]. Further
studies have shown the potential for microRNAs to distinguish
between cancer subtypes where histological diagnosis is complex
or impossible, to diagnose tumors of unknown origin and in
diagnosing cancer predisposition [4].
Investigations into the use of microRNAs as biomarkers for
early cancer detection have identified surprising blood and tissue
stability in contrast to mRNA [7,8], and the development of highly
sensitive and specific qPCR procedures is encouraging. However,
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already developed cancer [4], so the utility of microRNA as a
marker of cancer progression from precancerous through to early
invasive cancerous lesions remains unknown. Investigation of
microRNA expression in samples spanning the entire range of
histologically defined sample types, from normal to invasive
cancer, is clearly required to properly determine the utility of
microRNA expression levels as cancer biomarkers.
Cervical cancer is a disease for which stratification of
histological types from normal through to invasive carcinoma is
well characterized and supported by molecular techniques based
on HPV genotyping. However, given the enormous success of
cervical screening programs, only 35–65% CIN-3/CIS, 12–20%
CIN-2 and ,5% CIN-1 cases are expected to progress to more
severe forms of dysplasia or invasive cancer – suggesting that
markers with a higher predictive value for progression would be
highly desirable [9,10]. We therefore identified cervical cancer as
an ideal test case for which to follow changes in specific microRNA
expressions levels from normal through precancerous and
cancerous tissues. Past studies have identified a range of aberrantly
regulated microRNAs in cervical cancer cell lines, with mirs-127,
9, 203, 199a, 218, 21, 143, 205, 214,126, 15b, 16, 146a and 155
among the most common [3,11–17]. However, only one of these
studies included precancerous cervical specimens (CIN1-3), where
high biological variability was noted in the microRNA expression
levels, especially in normal samples (albeit with low sample sizes)
[16].
In this study we investigated the expression profiles of two
microRNAs (mir-21 and mir-143) and their previously validat-
ed target proteins in clinicals a m p l e sf r o mw o m e nw i t hH P V
infection without lesions, with histologically diagnosed pre-
cancerous lesions, or with invasive cancer (ICC), as well as
normal controls without HPV infection. The sequences were
chosen based on previous findings from other groups identify-
ing significant deregulation across a number of cervical cancer
cell lines and some limited fresh frozen samples [12]. Our
primary aim was to determine if there were significant
correlations between microRNA expression and histological
type which could point to a potential role for microRNA as an
early marker of the oncogenic potential of pre-lesional HPV
infection and/or of progression of precancer to cancer.
Secondly, we compared microRNA expression in clinical
samples and cancer cell lines to determine if cell lines should
continue to be used as a basis for clinical investigations. We
identified a significant association between mir-21 expression
and histological diagnosis, but no association with mir-143. We
also investigated the expression of known mir-21 target proteins
(PDCD4, PTEN (phosphatase and tensin homolog), TPM1
(tropomyosin 1)) by immunohistochemistry analysis and iden-
tified a significant association between cytoplasmic PDCD4
expression and histological diagnosis. We identified discrepan-
cies between the clinical samples and cervical cancer cell lines,
suggesting that clinical samples must be investigated for
validation purposes following discovery of candidate biomark-
ers in cell line discovery-focused studies.
Results
MicroRNA expression in cervical cancer cell lines
We investigated the expression of mir-21 and mir-143 in
cervical cancer cell lines with respect to (Normal (HRHPV-) in
order to confirm previous observations. Figure 1 shows that for all
three cancer cell lines tested (SiHa, CaSki, HeLa), there was no
consistent difference between mir-21 expression and that of
normal samples. However, mir-143 expression of all three cancer
cell lines was substantially decreased with respect to clinical
samples However, we have not attached statistical analysis to these
comparisons because of the different error distributions between
clinical samples and cell lines, and because we would only have
n=3 in the case of the cell lines for comparison.
MicroRNA expression in clinical samples
In contrast to cell line data, we observed a significant association
between mir-21 expression and histologic type in clinical samples,
but no association for mir-143 (Figure 2 and Table 1). Women
with ICC showed significantly increased mir-21 expression levels
compared to women with CIS/CIN2-3, CIN1, normal
(HRHPV+) and normal (HRHPV-) (ANOVA, p,0.0001). Fur-
thermore, women with CIS/CIN2-3 had marginally increased
mir-21 expression levels compared to women with CIN1 (pu=0.14
and pa=0.24) and normal (HRHPV+)( pu=0.07 and pa=0.14).
We found no association between age or HRHPV status and
histological type (data not shown). A cutoff of 5.06 best
distinguished ICC/Normal (HPV-) populations (determined from
ROC curve) and was 91% sensitive and 87% specific. Figure 2
shows how that cutoff faired for the other two histology groups.
Only 5% of the samples from women who are Normal (HPV+),
7% of CIN 1, and 24% of CIN 2-3/CIS samples had MIR-21
values greater than 5.06. Interestingly, 13% of samples from
women with Normal (HPV-) histology showed mir-21 expression
level greater than 5.06.
PDCD4, PTEN and TPM1 expression
In order to investigate the effect of mir-21 deregulation on
tissue-specific target protein expression in clinical samples, we
measured protein expression levels of PDCD4 and PTEN by
immunohistochemistry (IHC) in 72 of the samples tested for mir-
21 expression. TPM1 expression was evaluated on a subset of
Figure 1. Expression profiling data for mir-21 and mir-143 in
cervical cancer cell lines and normal specimens. Mir-143 was
significantly down-regulated in all three cervical cancer cell lines, in
agreement with previous studies. However, mir-21 was not significantly
different to the normal specimens, even though in previous studies mir-
21 has been observed to be significantly up-regulated in the same cell
lines.
doi:10.1371/journal.pone.0028423.g001
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epithelium was found to be below the threshold of detection by
immunohistochemistry. We observed a significant association
between cytoplasmic PDCD4 (cPDCD4) expression and sample
histology (Table 2, Figure 3 and Figure 4). Samples from women
with ICC had significantly lower cPDCD4 expression compared
to those with CIN2-3/CIS (pu=0.0005 or pa=0.003) and
marginally lower expression compared to (HRHPV+)( pu=0.03
or pa=0.11). Women in the normal (HRHPV-) group had
significantly lower cPDCD4 expression compared to CIS/CIN2-
3( pu=0.005orpa=0.02). There also appeared to be a marginal
decrease in nuclear PDCD4 (nPDCD4) in women with ICC in
comparison to those with CIN2-3/CIS. There was no significant
correlation between PDCD4 expression (nuclear or cytoplasmic)
and mir-21 expression in these samples, however we observed a
general grouping of ICC with high mir-21 but not PDCD4, and
CIN-2,3/CIS with higher PDCD4 but non-elevated mir-21
(Figure 4). There was also no association between PTEN protein
expression and sample histology or microRNA expression. We
considered analyzing IHC by both the frequency of the
maximum intensity score and the frequency of the predominant
intensity score. However, we observed similar results compared to
the composite score analysis and determined there is no
advantage for using the frequency of intensity scores over the
composite scores.
Discussion
While microRNA expression profiling has been shown to be
highly specific for cancer typing, tumor diagnosis and identifying
tumors of unknown origin, it is not yet clear if microRNAs can
perform as markers of disease progression – a crucial requirement
for identifying those conditions which require treatment. Ideally,
such markers of progression would show systematic changes in
expression in precancerous tissues, which correlate with disease
progression to invasive cancer. Clearly, this requires access to large
numbers of clinical samples which cover the range of histologically
defined tissue types involved in disease progression. In this study
we investigated the expression levels of two key MicroRNAs
identified in the literature (and their validated protein targets) in
cervical tissue stratified by histological diagnosis in order to
determine their utility as biomarkers for early cancer diagnosis.
We found that mir-21 expression was significantly increased only
in ICC with respect to other clinical samples and that mir-143
expression did not correlate with histology at all. Cervical cancer
cell line results, while consistent with previous studies on the same
cell lines, appeared to give discordant microRNA expression
results in comparison to clinical samples. Interestingly, PDCD4
protein expression increased in precancerous lesions then
decreased significantly in ICC, possibly as an effect of mir-21-
induced silencing. These results highlight the need for further
Figure 2. Expression profiling for (a) mir-21 and (b) mir-143 in 133 clinical samples stratified by histological diagnosis. In contrast to
the cell-line data presented in Figure 1, we observed a significant association between increased mir-21 expression an worsening histological
diagnosis, however no significant associations for mir-143. There was a significant difference between all histological groups (ANOVA, p-
value,0.0001) and furthermore, women with CIS/CIN2-3 had marginally higher mir-21 expression levels compared to those classified as Normal/
HRHPV+ (pu=0.0375 pa=0.0563).
doi:10.1371/journal.pone.0028423.g002
Table 1. MicroRNA expression in FFPE cervical specimens.
Normal (HPV-) (n=23) Normal (HPV+) (n=21) CIN1 (n=15) CIN2-3/CIS (n=51) ICC (n=23) p-Value*
Age 42.665.6 47.268.7 40.465.5 43.768.7 45.469.5 0.11
Mir-21 4.061.2 3.461.4 3.461.4 4.161.7 7.061.9 ,0.0001
Mir-143 21.261.2 21.561.5 22.762.1 21.662.8 21.762.7 0.38
*ANOVA.
doi:10.1371/journal.pone.0028423.t001
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expression levels of candidate MicroRNA biomarkers can be
assessed in pre-cancerous disease, where their utility in cancer
diagnostics would prove most beneficial. We identified key
inconsistencies in microRNA expression profiles in our clinical
specimens as compared to cervical cancer cell lines. However,
recent investigations show significant differences in microRNA
expression based on cell culture conditions suggesting that cell line
experiments may not be particularly informative when searching
for clinically relevant microRNAs [12]. Cheng et al. 2005 [18]
showed significant increase in HeLa cell growth and proliferation
in response to inhibition of mir-21, whereas Yao et al 2009 [14]
showed significant decrease in cell growth and proliferation for the
same treatment. Wang et al 2008 [12] further showed that
changing culture conditions from a monoculture to a suspension
raft culture led to a completely different set of significantly
deregulated microRNAs. Similar discordant results have been seen
in other studies investigating the relevance of cell culture models in
comparison to in vivo tissue of spheroidal cultures [19,20]. Also,
other gene/protein expression differences have recently been
identified, including the presence of WNT5A expression in gastric
cancers (not expressed in cell lines) [21] and differences in DNA
methylation [22] and gene expression [23] signatures between
colorectal carcinomas and colon cancer cell lines. Clearly, a key
problem with the cell line approach is that potential biomarkers
are identified in cells immortalized from invasive cancers – it is
often completely unknown if these biomarkers can be detected in
pre-cancerous disease, which requires analysis of clinical samples.
A further complication in the current study may be the racial
background (West African) in comparison to cancer cell lines
which are Caucasian – however little information is known about
such variation.
Increased mir-21 expression has been identified in a large
number of tumor types [24–29] and in this study has shown
significant association with the development of histologically-
defined ICC. Furthermore, our results show that mir-21 may be of
some utility in predicting the progression of pre-cancerous lesions
into ICC, as women with high mir-21 values may be expected to
progress. However, further studies involving larger sample sizes
and patient follow-up are required to investigate this aspect, as
there are clearly insufficient data for proper testing of this
hypothesis by splitting into training and testing sets. Furthermore,
while the mir-21 expression levels of women with normal
pathology with and without HRHPV infection are not statistically
different, the HRHPV- group showed approximately double the
number of samples above the optimal cut-off compared to the
HRHPV+ group. The significance of this result is again difficult to
quantify due to the relatively low sample sizes involved, but it may
indicate that a panel of biomarkers may be necessary to help
reduce false positives.
A number of studies have identified mir-143 as significantly
underexpressed in cancer, including breast and cervical cancers
[12,17,30]. Whilst we also observed significant underexpression in
cervical cancer cell lines with respect to normal (HRHPV-)
samples, we did not find any statistically significant associations
with respect to clinical samples from women across a wide
spectrum of neoplastic disease. Previous studies investigating
microRNA expression in cervical samples again show conflicting
results. Lee et al 2008 [11] did not include either mir-21 or mir-143
Figure 3. Micrographs showing PDCD4 staining of (a) Normal
(HRHVP-) specimen and (b) ICC specimen.
doi:10.1371/journal.pone.0028423.g003
Table 2. Protein expression results for 72 clinical samples.
Normal (HPV-) (n=15) Normal (HPV+) (n=15) CIN1 (n=7) CIN2-3/CIS (n=18) ICC (n=17) p-value*
Age 42.164.9 46.669.3 42.364.8 45.5610.6 46.4610.7 0.55
nPDCD4 122.0647.9 143.0649.3 124.3651.8 152.8661.4 110.9640.7 0.13
cPDCD4 73.3630.2 94.7631.4 87.9635.0 111.9650.8 65.6633.1 0.006
nPTEN 70.3640.8 81.7635.6 44.3637.2 68.1628.5 64.4646.9 0.32
cPTEN 64.0631.8 69.0629.3 47.9643.1 68.3628.2 69.7636.0 0.62
*ANOVA.
doi:10.1371/journal.pone.0028423.t002
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these species as being involved in cancer development; this
highlights a clear challenge in identifying potential biomarkers, in
cases where leading candidates are ignored. However, Wang et al
2008 [12] suggested that reduction of mir-143 was required for
tumor development whilst Lui et al 2007 [17] showed mixed results
for mir-143, mainly due to the low level of expression detected in
either normal or cancerous samples. Inconsistencies may be due to
the relatively low level mir-143 expression in cervical tissues,
which may require a more precise extraction method (e.g. laser
microdissection) for tumor extraction – none of the studies listed
here used such methods.
Previous studies revealed that PDCD4, PTEN and TPM1 are
all transcripts targeted by mir-21 in various tissues
[14,17,24,26,31,32] and that PTEN is progressively under-
expressed from normal tissue through to cervical cancer [33–
35]. One recent study has also reported reduced PDCD4
expression in cervical cancer cell lines [14] which is in agreement
with our findings in the clinical samples examined in this study. In
fact recent studies have demonstrated not only a direct relation
between PDCD4 expression and tumor progression (Wei et al,
2009 [36]) but also the key role of PDCD4 and mir-21 in apoptotic
inflammatory response (Sheedy et al, 2009 [37]). Moreover, recent
cell model studies support suggest a role for loss of PDCD4
expression in increased sensitivity of cells to agents that cause
DNA damage (Singh et al, 2009 [38]), all of which would be
expected to provide favourable conditions for tumor growth. Mice
expressing high levels of PDCD4 are also more resistant to tumor
growth in comparison to normal controls. We hypothesise that
cPDCD4 expression (and, to a lesser extent, nPDCD4 expression)
is increased in pre-cancerous specimens due to increased
apoptosis, followed by a sharp decrease in expression for ICC
specimens, where apoptotic mechanisms are subverted. Similar
trends have been observed for other tumor suppressor genes in
relation to oncogenesis and apoptosis [39,40]. Interestingly, we did
not identify any correlation between PTEN expression and
histological diagnosis; loss of expression has been noted previously,
and we have observed lower expression in a breast cancer study
using the same methods (data not shown).
In this study we have found that the expression level of mir-21
is significantly correlated with histological diagnosis of ICC. A
known target of mir-21, PDCD4 was also downregulated but
was not significantly correlated with mir-21 expression.
Expression of mir-143 was not correlated with histological
diagnosis of clinical samples, however it was significantly down-
regulated in cervical cancer cell lines. These findings are
important in the quest to gauge the utility of MicroRNA
biomarkers for diagnostic applications, a key component of
which is to measure expression levels in precancerous tissues as
well as normal and invasive cancers. Clearly, future work must
focus on clinically relevant samples, in which predictive markers
expressed in pre-cancerous tissue can be identified for further
validation.
Materials and Methods
Selection of microRNAs
MiRs investigated in this study were chosen based on previous
observations in the literature (Table 3). We specified that each
microRNA should also have an experimentally verified mRNA
target or set of target genes and at least one of the predicted targets
had to be reported as involved in oncogenesis and progression in
cervical or other neoplasms (based on sequences in the miRBase
database [41–43]). MiR-21 is reported to be overexpressed in a
number of cancers [29,44] and targets transcripts of the PTEN
[24], TPM1 [26] and PDCD4 [14,31,32] genes, whilst miR-143 is
underexpressed in many cancers and targets ERK5 transcripts
[17,29,30]. Both mir-21 overexpression and mir-143 under-
expression have been observed in cervical cancer cell lines and
clinical specimens [12,17].
Samples
Clinical specimens were collected from the Dantec Oncology
Clinic, Dakar, Senegal from studies of cervical cancer [45]; all
study procedures were approved by the institutional review
boards of the University of Washington (Seattle, WA) and
University of Dakar (Dakar, Senegal) and informed written
consent was provided by study participants. Histological diagno-
Figure 4. Protein expression data measured by immunohistochemistry for cytoplasmic PDCD4 stratified by histological diagnosis.
Here we observed a significant association between cytoplasmic PDCD4 expression and sample histology.
doi:10.1371/journal.pone.0028423.g004
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of Pathology, Harborview Medical Center, Seattle, WA by a
pathologist (NBK). Samples collected included 142 cervical
biopsies preserved as FFPE tissue blocks. HPV genotyping was
performed as described previously [46], with High-Risk HPV
(HRHPV) subtypes HPV16/18/26/31/33/35/39/45/51/52/
53/56/58/59/66/67/68/73/82 as defined by Munoz et. al.
2006 [47]. Clinical specimens were grouped according to
histological diagnosis, with groups defined by treatment regimens
per current guidelines [48]. Normal (HRHPV-) identified those
women with a normal histology and a negative test result for
HRHPV (n=23). Normal (HRHPV+) indicated those women
with a normal histology and a positive test for HRHPV (n=21).
Mildly dysplastic CIN1 lesions (n=15) typically spontaneously
regress and women with these lesions are usually followed with
repeat Pap smear. Women with precancerous CIN2-3/CIS
lesions (n=51) would all be referred for treatment to prevent
development of invasive disease ICC (n=23). These groupings
allowed us to determine if the microRNA biomarkers under
investigation could identify various stages of neoplastic disease
which require different clinical management. The average age of
the 133 subjects from who clinical specimens were used was 44
ranging from 29 to 72 years. All four histologic groups were
frequency matched on age in order to achieve similar age
distributions and means, which ranged between 43 and 45 years.
Cell lines and culture media were purchased from ATCC and
Gibco (Invitrogen, Carlsbad, CA).
MicroRNA qPCR expression analysis
Extraction of microRNA from blocks was performed using the
RecoverAll Total Nucleic Acid Isolation Kit (Applied BioSys-
tems, Foster City, CA), according to manufacturer’s instructions.
The only alteration was that for cell line extraction, the
deparaffination steps were omitted on the advice of Applied
Biosystems staff. Reverse transcription (RT) reactions and
quantitative polymerase chain reactions (qPCR) were performed
using the MicroRNA TaqMan Reverse Transcription Kit and
the TaqMan MicroRNA Assays (Applied BioSystems) for mir-21,
mir-143 and RNU6B control shRNA. RT and qPCR for the
RNU6B control shRNA analysis was performed side-by-side with
the mir-21 and mir-143 reactions for each sample. A standard
curve was generated by extracting total RNA from VK2 cells and
performing RT reactions on 10-fold dilutions, subsequently
including each serial dilution in each qPCR run, throughout
the whole study.
Immunohistochemistry
PDCD4 rabbit polyclonal antibody and TPM1 mouse mono-
clonal antibody was purchased from Abcam (Abcam Inc.,
Cambridge MA, ab51495, ab17784 respectively), PTEN mouse
monoclonal antibody was purchased from Dako (Dako Corpora-
tion; Carpinteria, CA, clone 6H2.1) Four-micron sections of
formalin-fixed paraffin-embedded tissue were cut and placed on
Superfrost Plus microscope slides. The tissue sections were
deparaffinized and rehydrated through a series of graded alcohols.
Antigen retrieval was carried out with Tris/EDTA pH 9.0 buffer
in a tabletop autoclave. Endogenous peroxidase activity was
blocked with 3% H2O2. Primary antibodies were varied to
determine the optimal antibody concentration resulting in the
most intense staining with no background. Antibodies for PDCD4
were diluted 1:2000 and PTEN antibody was diluted to 1:500 and
applied to each slide. TPM1 antibody was diluted to 1:100.The
slides were washed in ImmPRESS (Vector Laboratories; Burlin-
game, CA), then an anti-mouse (for PTEN and TPM1) and an
anti-rabbit (for PDCD4) IgG polymerized reporter enzyme was
applied to each tissue. Color development was accomplished by
incubation in diaminobenzidine (Dako). The slides were counter-
stained in hematoxylin (Dako), dehydrated through graded
alcohols, cleared in xylene, and coverslipped with permanent
mounting media. A negative tissue control was run on each tissue,
where antibody diluent buffer was substituted for the primary
antibody. In addition, positive control tissues known to express the
antigen in question were run in conjunction with each batch of
slides. PDCD4 and PTEN staining was evaluated semi-quantita-
tively using the H-score scoring method [49]. This method of
quantification takes into account the staining intensity and the
percentage of cells staining at a particular intensity. Staining
intensity was scored as 0 (no staining), 1 (weak staining), 2
(moderate staining), 3 (intense staining). Each intensity score was
multiplied by the percentage of cells staining at that level. The
resulting values were summed to yield a composite score ranging
from 0 to 300. PDCD4 and PTEN expression was evaluated in
both the nuclear and cytoplasmic compartments.
Statistical Methods
Taqman qPCR reactions were performed in triplicate redun-
dancy and the Ct values converted to a ratio with respect to the
RNU6B control. Non-cancer controls were frequency age-
matched to cases with invasive cancer. Values of both microRNAs
were log10-transformed in order to normalize the distribution of
these measurements for all statistical analyses. ANOVA was used
to compare all histologic groups with respect to the continuous
factors of interest. P-values are reported as unadjusted (pu) and
adjusted for multiple comparisons using false discovery rates (pa).
Receiver Operating characteristic (ROC) curves were used to
assess the predictability of cervical disease progression. Optimal
cutoffs were determined to best distinguish Normal (HPV-) women
from women with ICC. A two-sided 0.05 test level determined
statistical significance for all analyses. All analyses were conducted
using SAS version 9.2 (SAS Institute Inc., Cary, NC).
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